search
Back to results

Safety, Blood Levels and Effects of AUT00201 in Patients With MEAK (AUT022201)

Primary Purpose

Myoclonus Epilepsies, Progressive

Status
Recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
AUT00201
Placebo
Sponsored by
Autifony Therapeutics Limited
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Myoclonus Epilepsies, Progressive focused on measuring MEAK, EPM7

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Male or female patients aged 18 years or older at time of consenting. Diagnosed with MEAK, based on documented genetic evidence of the presence of the KCNC1 (c.959G>A; p.Arg320His) variant. If take anticonvulsants, must be on a stable anticonvulsant regiment for at least 30 days prior to Visit 1 and anticipated to remain stable throughout the study or if not on an anticonvulsant regimen, must be stable in regards to seizures for at least 30 days prior to Visit 1 and anticipated to remain stable throughout the study. Must be able to participate and willing to give written informed consent. If patient is unable to provide written informed consent, a legally authorized representative can sign on their behalf. Must be willing to perform study assessments and comply with the study protocol. If the patient is dependent on a caregiver and/or will need assistance either travelling to the site, whilst attending clinic visits and/or helping to document study assessment responses provided by the patient (eg, questionnaires administered on a tablet device), they must have an identified caregiver, considered reliable by the Investigator, to provide support to the patient for the duration of the study. The caregiver must be willing and able to provide support to the patient and, if required, stay for the duration of the study. Medically stable based on Investigator's judgement for at least 90 days prior to Visit 1. Women of childbearing potential must have a negative urine pregnancy test on Visit 2. If a vagal nerve stimulator is used, it must be implanted at least 150 days before Day. -1, and parameters must be stable for at least 30 days before Visit 1 and expected to remain stable throughout the study. If a ketogenic diet is followed, it must be stable for at least 30 days before Visit 1 and expected to remain stable throughout the study. Willing to comply with contraceptive requirements. Able to speak, read and understand English at a fluent level Exclusion Criteria: Known pathogenic mutation in another gene that causes epilepsy or a different mutation in the KCNC1 gene than the c.959G>A variant. Clinically significant metabolic, hepatic, hematological, pulmonary, cardiovascular, gastrointestinal, or urological disorder. Clinically significant abnormal vital signs or laboratory test results. Hypersensitivity to AUT00201 or any of the excipients. Any medical condition or other factors, as judged by the Investigator, which may interfere with the patient's participation in this study and/or compromise the patient's ability to safely complete the study. Known to abuse drugs or those who test positive on urine screen for drugs of abuse will be excluded based on Investigator's judgement. Positive hepatitis B surface antigen or hepatitis C antibody. Clinically significant abnormality on the 12-lead electrocardiogram. Having received an investigational product 90 days prior to Visit 1. Currently using felbamate <1 year prior to Visit 1, or any evidence of ongoing hepatic or bone marrow dysfunction associated with current/prior felbamate treatment. Patients who are currently using felbamate for >1 year prior to Visit 1 and have no evidence of ongoing hepatic or bone marrow dysfunction associated with felbamate treatment are allowed. Currently using vigabatrin and having received vigabatrin for <2 years prior to Visit 1. Suicidal ideation with some intent to act within 6 months prior to Visit 1 based upon response in the Columbia-Suicide Severity Rating Scale (positive response to questions 4 or 5 of the suicidal ideation section) and as judged by the Investigator as having a significant impact on trial participation or patient safety. History of suicidal behavior within 1 year prior to Visit 1.

Sites / Locations

  • University of Pennsylvania, Penn Epilepsy CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Experimental: AUT00201

Experimental: Placebo

Arm Description

Single dose (oral, capsule) of AUT00201

Single dose matching placebo oral capsules

Outcomes

Primary Outcome Measures

Number of Participants With Treatment-Related Adverse Events after Single Dose Treatment of AUT00201 compared to Placebo

Secondary Outcome Measures

Change from baseline in cortical inhibition
Short interval and long interval cortical inhibition as measured by paired-pulse TMS EMG
Pharmacokinetics: Maximum Plasma Concentrations (Cmax) of AUT00201
Pharmacokinetics: Area under the plasma concentration-time curve (AUC) of AUT00201

Full Information

First Posted
April 18, 2023
Last Updated
June 29, 2023
Sponsor
Autifony Therapeutics Limited
search

1. Study Identification

Unique Protocol Identification Number
NCT05873062
Brief Title
Safety, Blood Levels and Effects of AUT00201 in Patients With MEAK
Acronym
AUT022201
Official Title
A Randomized, Double-blind, Placebo-controlled, Crossover Study of the Effects of Single Doses of AUT00201 in Patients With Myoclonus Epilepsy and Ataxia Due to Potassium (K+) Channel Mutation (MEAK)
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 12, 2023 (Actual)
Primary Completion Date
December 2023 (Anticipated)
Study Completion Date
December 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Autifony Therapeutics Limited

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
A randomized, double-blind, placebo-controlled, crossover study to assess the safety, tolerability, and pharmacokinetics of single doses of AUT00201 at 100 mg or matching placebo in patients with myoclonus epilepsy and ataxia due to potassium channel mutation (MEAK).
Detailed Description
8 to 10 patients aged 18 years and older, diagnosed with MEAK will be enrolled in the study. Patients will be administered a single dose of AUT00201 and matching placebo in a crossover design. The study is comprised of an outpatient screening and procedure orientation followed by approximately 4.5 days of an inpatient stay at a clinical research unit. After screening/orientation (Visit 1), and baseline assessments (Visit 2), patients will be administered a single dose of 100 mg of AUT00201 or matching placebo the morning of Visit 3. PK assessments will be done at Visits 3, 4, 5, and 6 from predose and up to 27 hours postdose. Visit 4 will be a washout day for patients. At Visit 5 patients will be administered the crossover treatment. At Visit 6 patients will be discharged from the unit. Safety and tolerability assessments will be conducted throughout. PD parameters will also be assessed. Patients will be followed up by telephone 14 days after discharge.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Myoclonus Epilepsies, Progressive
Keywords
MEAK, EPM7

7. Study Design

Primary Purpose
Basic Science
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Model Description
Subjects will be randomized in a 1:1 ratio to one of the two treatments with 4-5 subjects per treatment sequence. Each subject will receive both treatments (100 mg AUT00201 and placebo) with a washout period of 1 day between single doses.
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
10 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Experimental: AUT00201
Arm Type
Experimental
Arm Description
Single dose (oral, capsule) of AUT00201
Arm Title
Experimental: Placebo
Arm Type
Placebo Comparator
Arm Description
Single dose matching placebo oral capsules
Intervention Type
Drug
Intervention Name(s)
AUT00201
Intervention Description
Single oral dose
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Single oral dose
Primary Outcome Measure Information:
Title
Number of Participants With Treatment-Related Adverse Events after Single Dose Treatment of AUT00201 compared to Placebo
Time Frame
14 Days
Secondary Outcome Measure Information:
Title
Change from baseline in cortical inhibition
Description
Short interval and long interval cortical inhibition as measured by paired-pulse TMS EMG
Time Frame
6 Days
Title
Pharmacokinetics: Maximum Plasma Concentrations (Cmax) of AUT00201
Time Frame
4 Days
Title
Pharmacokinetics: Area under the plasma concentration-time curve (AUC) of AUT00201
Time Frame
4 Days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female patients aged 18 years or older at time of consenting. Diagnosed with MEAK, based on documented genetic evidence of the presence of the KCNC1 (c.959G>A; p.Arg320His) variant. If take anticonvulsants, must be on a stable anticonvulsant regiment for at least 30 days prior to Visit 1 and anticipated to remain stable throughout the study or if not on an anticonvulsant regimen, must be stable in regards to seizures for at least 30 days prior to Visit 1 and anticipated to remain stable throughout the study. Must be able to participate and willing to give written informed consent. If patient is unable to provide written informed consent, a legally authorized representative can sign on their behalf. Must be willing to perform study assessments and comply with the study protocol. If the patient is dependent on a caregiver and/or will need assistance either travelling to the site, whilst attending clinic visits and/or helping to document study assessment responses provided by the patient (eg, questionnaires administered on a tablet device), they must have an identified caregiver, considered reliable by the Investigator, to provide support to the patient for the duration of the study. The caregiver must be willing and able to provide support to the patient and, if required, stay for the duration of the study. Medically stable based on Investigator's judgement for at least 90 days prior to Visit 1. Women of childbearing potential must have a negative urine pregnancy test on Visit 2. If a vagal nerve stimulator is used, it must be implanted at least 150 days before Day. -1, and parameters must be stable for at least 30 days before Visit 1 and expected to remain stable throughout the study. If a ketogenic diet is followed, it must be stable for at least 30 days before Visit 1 and expected to remain stable throughout the study. Willing to comply with contraceptive requirements. Able to speak, read and understand English at a fluent level Exclusion Criteria: Known pathogenic mutation in another gene that causes epilepsy or a different mutation in the KCNC1 gene than the c.959G>A variant. Clinically significant metabolic, hepatic, hematological, pulmonary, cardiovascular, gastrointestinal, or urological disorder. Clinically significant abnormal vital signs or laboratory test results. Hypersensitivity to AUT00201 or any of the excipients. Any medical condition or other factors, as judged by the Investigator, which may interfere with the patient's participation in this study and/or compromise the patient's ability to safely complete the study. Known to abuse drugs or those who test positive on urine screen for drugs of abuse will be excluded based on Investigator's judgement. Positive hepatitis B surface antigen or hepatitis C antibody. Clinically significant abnormality on the 12-lead electrocardiogram. Having received an investigational product 90 days prior to Visit 1. Currently using felbamate <1 year prior to Visit 1, or any evidence of ongoing hepatic or bone marrow dysfunction associated with current/prior felbamate treatment. Patients who are currently using felbamate for >1 year prior to Visit 1 and have no evidence of ongoing hepatic or bone marrow dysfunction associated with felbamate treatment are allowed. Currently using vigabatrin and having received vigabatrin for <2 years prior to Visit 1. Suicidal ideation with some intent to act within 6 months prior to Visit 1 based upon response in the Columbia-Suicide Severity Rating Scale (positive response to questions 4 or 5 of the suicidal ideation section) and as judged by the Investigator as having a significant impact on trial participation or patient safety. History of suicidal behavior within 1 year prior to Visit 1.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michael Gelfand, MD
Organizational Affiliation
Penn Epilepsy Center, Department of Neurology
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Pennsylvania, Penn Epilepsy Center
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Melissa Johnston Esparza
Phone
215-614-0520
Email
melissa.johnstonesparza@pennmedicine.upenn.edu

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Safety, Blood Levels and Effects of AUT00201 in Patients With MEAK

We'll reach out to this number within 24 hrs